Go Pro
NASDAQ:IMCC

IM Cannabis Q4 2025 Earnings Report

IM Cannabis logo
$3.09 -1.14 (-26.95%)
As of 04:00 PM Eastern

IM Cannabis EPS Results

Actual EPS
-$25.80
Consensus EPS
$2.58
Beat/Miss
Missed by -$28.38
One Year Ago EPS
N/A

IM Cannabis Revenue Results

Actual Revenue
$11.25 million
Expected Revenue
$15.66 million
Beat/Miss
Missed by -$4.41 million
YoY Revenue Growth
N/A

IM Cannabis Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Monday, March 30, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

IM Cannabis' Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

IM Cannabis Earnings Headlines

Critical Analysis: Indivior (OTCMKTS:INVVY) & IM Cannabis (NASDAQ:IMCC)
Penny Stocks To Follow Now - September 18th
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Top Cannabis Stocks To Watch Now - September 18th
Cannabis Stocks To Watch Now - September 19th
Penny Stocks To Consider - September 19th
See More IM Cannabis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IM Cannabis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IM Cannabis and other key companies, straight to your email.

About IM Cannabis

IM Cannabis (NASDAQ:IMCC) is a medical cannabis company that operates primarily in Israel and Germany. The company develops, imports, distributes and sells medical cannabis products through the IMC brand and related product lines.

Its product portfolio includes medical cannabis flower, oils and other cannabis-based products. In Israel, IM Cannabis serves the regulated medical cannabis market through activities that include product sourcing, distribution and sales to authorized patients and pharmacies. In Germany, the company participates in the medical cannabis supply chain, including the wholesale distribution of pharmaceutical-grade cannabis products.

IM Cannabis was established as an international medical cannabis operator and became publicly traded in North America in 2021. The company previously had Canadian operations but has since focused its business on its core markets in Israel and Germany. Oren Shuster has served as the company’s chief executive officer.

View IM Cannabis Profile